Investors Purchase High Volume of Emergent BioSolutions Put Options (NYSE:EBS)

Emergent BioSolutions Inc. (NYSE:EBS) was the target of some unusual options trading on Wednesday. Investors bought 3,153 put options on the company. This is an increase of approximately 344% compared to the average daily volume of 710 put options.

Institutional Investors Weigh In On Emergent BioSolutions

A number of institutional investors have recently added to or reduced their stakes in EBS. Quantbot Technologies LP grew its position in Emergent BioSolutions by 218.7% during the third quarter. Quantbot Technologies LP now owns 8,700 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 5,970 shares during the period. CoreCap Advisors LLC acquired a new position in shares of Emergent BioSolutions during the fourth quarter worth about $33,000. Laurion Capital Management LP acquired a new position in shares of Emergent BioSolutions during the third quarter worth about $37,000. Tower Research Capital LLC TRC lifted its stake in shares of Emergent BioSolutions by 52.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 19,867 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 6,823 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Emergent BioSolutions during the first quarter worth about $57,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Analyst Ratings Changes

Separately, Benchmark reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Emergent BioSolutions in a research report on Thursday, April 11th.

Emergent BioSolutions Price Performance

Shares of NYSE:EBS opened at $1.93 on Thursday. The company has a market cap of $101.11 million, a P/E ratio of -0.13 and a beta of 1.20. The company has a quick ratio of 0.54, a current ratio of 1.04 and a debt-to-equity ratio of 0.69. Emergent BioSolutions has a 52 week low of $1.42 and a 52 week high of $10.88. The business has a fifty day simple moving average of $2.45 and a 200-day simple moving average of $2.22.

Emergent BioSolutions (NYSE:EBS) last posted its quarterly earnings results on Wednesday, March 6th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.44). Emergent BioSolutions had a negative net margin of 72.11% and a negative return on equity of 37.35%. The firm had revenue of $276.60 million for the quarter, compared to analysts’ expectations of $247.63 million. During the same period last year, the firm posted ($0.31) EPS.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.